Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06715189

Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
All
Age
30 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum Adiponectine and Resistincorrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
DIAGNOSTIC_TESTfibroscanhepatic fibrosis detection in type 2 diabetes mellutis

Timeline

Start date
2024-12-01
Primary completion
2025-12-01
Completion
2025-12-30
First posted
2024-12-04
Last updated
2024-12-04

Source: ClinicalTrials.gov record NCT06715189. Inclusion in this directory is not an endorsement.

Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Me (NCT06715189) · Clinical Trials Directory